-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35

Benzinga·10/20/2026 12:27:01
Listen to the news
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.